Viroptic Related Published Studies
Well-designed clinical trials related to Viroptic (Trifluridine Ophthalmic)
A prospective, masked clinical trial of trifluridine, dexamethasone, and artificial tears in the treatment of epidemic keratoconjunctivitis. [1993.05]
Well-designed clinical trials possibly related to Viroptic (Trifluridine Ophthalmic)
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind,
randomised, placebo-controlled phase 2 trial. [2012]
Slitlamp biomicroscopy and photographic image analysis of herpes simplex virus stromal keratitis. [2009.02]
Efficacy of four antiviral agents in the treatment of uncomplicated herpetic keratitis. [1995.08]
Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. [1994.12]
Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. [1994.12]
Phosphonoformate (foscarnet, PFA) versus trifluorthymidine in the treatment of keratitis dendritica in the human. A double-blind, randomized, preliminary trial. [1992.10]
Randomised double-blind trial of bromovinyldeoxyuridine (BVDU) and trifluorothymidine (TFT) in dendritic corneal ulceration. [1991.11]
Bromovinyldeoxyuridine (BVDU) and trifluorothymidine (TFT) in dendritic corneal ulceration: a double blind controlled study. [1991]
[Epidemic keratoconjunctivitis: treatment results during an epidemic] [1990.09]
A comparison between acyclovir and trifluorothymidine ophthalmic ointment in the treatment of epithelial dendritic keratitis. A double blind, randomized parallel group trial. [1989.02]
An in vitro method which assesses corneal epithelial toxicity due to antineoplastic, preservative and antimicrobial agents. [1989]
Other research related to Viroptic (Trifluridine Ophthalmic)
[Trifluridine therapy in herpetic in keratitis] [2004.04]
Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model. [1999.02]
Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis. [1998.06]
Delivery of trifluridine to human cornea and aqueous using collagen shields. [1998.04]
Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). AIDS Clinical Trials Group. [1996.06.01]
Therapeutic response of herpes simplex virus-induced corneal edema to trifluridine in combination with immunosuppressive agents. [1991.08]
Trifluridine decreases ocular HSV-1 recovery, but not herpetic lesions after timolol iontophoresis. [1989.04]
Toxicity and clearance of a combination of liposome-encapsulated ganciclovir and trifluridine. [1989]
Other possibly related research studies
Therapeutic interventions for herpes simplex virus epithelial keratitis. [2008.01.23]
Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection. [2008.02]
Is herpes simplex virus keratitis a different disease in children? [2008.01]
Evidence-based treatment of herpes simplex virus keratitis: a systematic review. [2007.07]
Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. [2007.06]
Therapeutic interventions for herpes simplex virus epithelial keratitis. [2007.01.24]
The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. [2007.01.15]
Gateways to clinical trials. [2006.10]
Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine. [2007.01]
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. [2006.09.15]
Corneal ulceration associated with naturally occurring canine herpesvirus-1 infection in two adult dogs. [2006.08.01]
Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies. [2006]
Herpes simplex keratitis misdiagnosed as rheumatoid arthritis-related peripheral ulcerative keratitis. [2005.11]
Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. [2005.08]
Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells. [2005.03]
Herpes simplex uveitis. [2004.03]
Ocular complications in the Department of Defense Smallpox Vaccination Program. [2004.11]
Efficacy of antiviral agents in feline herpetic keratitis: results of an in vitro study. [2004.08]
Herpes simplex virus keratitis in children. [2004.09]
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. [2004.09]
[The latest in herpes simplex keratitis therapy] [2004.05]
Antiviral drugs in current clinical use. [2004.06]
Arthrographis keratitis mimicking acanthamoeba keratitis. [2004.04]
Ocular vaccinia following exposure to a smallpox vaccinee. [2004.03]
New onset of herpes simplex virus epithelial keratitis after penetrating keratoplasty. [2004.03]
Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model. [2004.02]
Interventions for herpes simplex virus epithelial keratitis. [2003]
Ocular complications of smallpox vaccination. [2003.08]
In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model. [2003.06]
Management of acyclovir-resistant herpes simplex virus. [2003.04]
The effect of roscovitine on herpetic keratitis. [2003.06]
Recurrence of keratitis after excimer laser keratectomy. [2003.01]
Atypical presentation of Acanthamoeba keratitis. [2001.10]
Efficacy of polyclonal antibodies for treatment of ocular herpes simplex infection. [2001.07]
Effect of famciclovir on herpes simplex virus type 1 corneal disease and establishment of latency in rabbits. [2001.07]
Effects of topical unoprostone and latanoprost on acute and recurrent herpetic keratitis in the rabbit. [2001.05]
Interventions for herpes simplex virus epithelial keratitis. [2001]
Contact dermatitis from topical antiviral drugs. [2001.05]
The treatment of herpes simplex virus epithelial keratitis. [2000]
Current recommendations for the treatment of genital herpes. [2000.12]
Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. [2000.08]
Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides. [2000.05.15]
The impact of the herpetic eye disease studies on the management of herpes simplex virus ocular infections. [1999.08]
Cidofovir and experimental herpetic stromal disease. [1999.07]
[Herpetic keratitis. Clinical and therapeutic aspects] [1997]
Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis. Herpetic Eye Disease Study Group. [1996.11]
Clinical characteristics of acyclovir-resistant herpetic keratitis and experimental studies of isolates. [1996.08]
Treatment of cats with ocular disease attributable to herpesvirus infection: 17 cases (1983-1993). [1995.09.01]
Topical interferon alpha-2a treatment of herpes simplex keratitis resistant to multiple antiviral medications in an immunosuppressed patient. [1995.05]
Presumed ophthalmic herpes zoster after contralateral cataract extraction. [1995.02]
HPMPC, a broad-spectrum topical antiviral agent, inhibits herpes simplex virus type 1 replication and promotes healing of dendritic keratitis in the New Zealand rabbit ocular model. [1994.11]
Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. [1994.03]
Modulation of ricin toxicity in mice by biologically active substances. [1994.03]
Antivirals for the treatment of herpesvirus infections. [1993.07]
Topical immunoglobulins for epithelial herpes simplex keratitis. [1993]
Delayed onset of varicella keratitis. [1992.09]
Recurrent herpetic keratitis during topical acyclovir application. [1992.07]
Persistence of herpes simplex virus DNA in rabbit corneal cells. [1992.07]
Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections. [1992.07]
A murine model of herpes simplex virus-induced ocular disease for antiviral drug testing. [1992.03]
Potentiation of the antitumor activity of 5-trifluoromethyl-2'-deoxyuridine by the use of depot forms of the parent compound. [1992]
Cutaneous herpes simplex virus infections. [1991.05]
Herpes simplex dendritic keratitis after keratoplasty. [1991.04.15]
Antitumor activity of FTC-092, a masked 5-trifluoromethyl-2'-deoxyuridine derivative. [1991]
Bromovinyldeoxyuridine treatment of herpetic keratitis clinically resistant to other antiviral agents. [1991]
Use of collagen shields in the treatment of herpetic keratitis. [1991]
Emergence of cross-resistant herpes simplex virus following topical drug therapy in rabbit keratitis. [1991]
The development of corneal edema in herpes simplex virus type 1-infected rabbits following termination of therapy for corneal stromal disease. [1991]
Collagen shield delivery of trifluorothymidine. [1990.11]
Treatment of ocular disease in eczema herpeticum. [1990.09.15]
Comparative laboratory diagnosis of experimental herpes simplex keratitis. [1990.01.15]
New acquisitions in the chemotherapy of viral infections. [1990]
Herpes simplex keratitis in patients with acquired immune deficiency syndrome. [1989.10]
Evolution of therapy for cytomegalovirus infection. [1988.07]
Antiviral chemotherapy today and tomorrow. [1988]
Retinal toxicity of combination antiviral drugs in an animal model. [1987.10]
Intravitreal liposome-encapsulated trifluorothymidine in a rabbit model. [1987.09]
Improved delivery through biological membranes XXV. Enhanced and sustained delivery of trifluorothymidine to the brain using a dihydropyridine in equilibrium pyridinium salt type redox delivery system. [1987.05]
Effective treatment of ocular HSK with a human apolipoprotein E mimetic peptide in a mouse eye model. [2008.10]
Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent. [2008.11]
Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. [2008.10]
|
